Work

Early Time Course of Symptom Improvement With Remibrutinib in Chronic Spontaneous Urticaria: Pooled Post Hoc Analyses of the REMIX ‐1/2 Phase 3 Studies

Year: 2026

Type: article

Abstract: Summary We undertook a post hoc, sponsor‐funded analysis of data from two recent clinical trials in CSU. Remibrutinib numerically improved CSU symptoms at 12 h; meaningful effects persisted from Day‐2 through Week‐52.

Source: Clinical & Experimental Allergy

DOI: 10.1111/cea.70450

Authors: Gordon Sussman, Nadine Chapman‐Rothe, Tao Ding, Atsushi Fukunaga, Ana Maria Giménez‐Arnau, Michihiro Hide, Mark Lebwohl, Paula G. P. Machado, El‐Djouher Martzloff, Giselle Mosnaim, Christine‐Elke Ortmann, Petra Staubach, Hui Tang, Ansgar Weyergraf, Bin Yang, John Reed

Institutions: University of Toronto, Novartis (Switzerland), Osaka Medical and Pharmaceutical University, Universitat Pompeu Fabra, Hiroshima University, Hiroshima City Hiroshima Citizens Hospital, Icahn School of Medicine at Mount Sinai, University Medical Center of the Johannes Gutenberg University Mainz, Shanghai Medical College of Fudan University, Fudan University, Huashan Hospital, Leiber (Germany), Southern Medical University, Churchill Hospital

Language: English

Topic: Urticaria and Related Conditions

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

Open Access status: hybrid

Estimated APC paid: $4,760

OpenAlex ID: W7222882165

FWCI:

Cites: 6

Cited by:

Related to: